---
schema_version: '1.0'
id: government-20260918-fe5a68
title: Biosimilar User Fee Act III Future Needs in the Development of Interchangeable
  Products Post-Workshop; Draft Strategy Document
content_kind: government-document
url: https://www.federalregister.gov/documents/2026/09/18/2026-19166/biosimilar-user-fee-act-iii-future-needs-in-the-development-of-interchangeable-products
url_hash: fe5a68d526ec88a989539693624a604b51a020f49da2dd3c461c66e543fce192
canonical_url: https://www.federalregister.gov/documents/2026/09/18/2026-19166/biosimilar-user-fee-act-iii-future-needs-in-the-development-of-interchangeable-products
source: us-federal-register
category: government/us
category_raw: Notice
country: us
region: us
tags: []
lang: en
published_at: '2026-09-18T00:00:00Z'
fetched_at: '2026-09-18T12:26:01.727101Z'
updated_at: '2026-09-18T13:49:36Z'
status: published
content_hash: d8ac41fb61c8b0026b12c220848ccd31a8f7178db300d166fece49e4a4d63f1e
content_changed_at: null
license_note: full
license_basis: public-domain-17usc105
body_available: false
attribution: 'Source: Office of the Federal Register, National Archives and Records
  Administration'
license_rule: source:us-federal-register
summary: 'The Food and Drug Administration (FDA or Agency) is announcing the publication
  of a draft strategy document titled "BsUFA III Future Needs in the Development of
  Interchangeable Products Post-Workshop Strategy Document" (Strategy Document). This
  draft Strategy Document is intended to summarize the discussion that occurred at
  the FDA public workshop, "Advancing the Development of Interchangeable Products:
  Identifying Future Needs," held on September 19, 2025, and to describe FDA''s future
  directions to support interchangeable biosimilar products. FDA is issuing this draft
  Strategy Document to fulfill a commitment FDA made in the Biosimilar User Fee Act
  (BsUFA) reauthorization commitment letter for fiscal years 2023 through 2027 (BsUFA
  III) to publish a post-workshop draft strategy document for public comment.'
summary_source: official
summary_en: 'The Food and Drug Administration (FDA or Agency) is announcing the publication
  of a draft strategy document titled "BsUFA III Future Needs in the Development of
  Interchangeable Products Post-Workshop Strategy Document" (Strategy Document). This
  draft Strategy Document is intended to summarize the discussion that occurred at
  the FDA public workshop, "Advancing the Development of Interchangeable Products:
  Identifying Future Needs," held on September 19, 2025, and to describe FDA''s future
  directions to support interchangeable biosimilar products. FDA is issuing this draft
  Strategy Document to fulfill a commitment FDA made in the Biosimilar User Fee Act
  (BsUFA) reauthorization commitment letter for fiscal years 2023 through 2027 (BsUFA
  III) to publish a post-workshop draft strategy document for public comment.'
summary_omitted_reason: null
redistribution: true
keywords_en:
- Act
- Active_Rooster_Lists
- AU Pre-Election Needs Assessment Mission
- Biosimilar
- Development
- Document
- Draft
- Fee
- Future
- III
- IIIT-Hyderabad
- Interchangeable
- Needs
- NovFeed
- Post-Workshop
- Products
- public policy
- Strategy
- Technical Capability Notice
- the
- U.S. Food and Drug Administration (FDA
- United States government
- USER
entities_en:
- name: Active_Rooster_Lists
  type: concept
- name: AU Pre-Election Needs Assessment Mission
  type: event
- name: IIIT-Hyderabad
  type: location
- name: NovFeed
  type: organization
- name: Technical Capability Notice
  type: concept
- name: U.S. Food and Drug Administration (FDA
  type: UNKNOWN
- name: USER
  type: person
topics_en:
- public policy
- United States government
numeric_facts: []
provenance:
  doc_id: 2026-19166
  doc_id_scheme: fr_docnum
  issuer:
  - Health and Human Services Department
  - Food and Drug Administration
  doc_type: Notice
  subtype: null
  action: Notice of availability.
  significant: null
entities:
- name: U.S. Food and Drug Administration (FDA
  type: UNKNOWN
- name: Technical Capability Notice
  type: concept
- name: USER
  type: person
- name: NovFeed
  type: organization
- name: Active_Rooster_Lists
  type: concept
- name: IIIT-Hyderabad
  type: location
- name: AU Pre-Election Needs Assessment Mission
  type: event
key_facts: []
related: []
related_auto:
- name: Prisoner No. 626710 is Present
  type: content
  weight: 2.0
- name: Ocrevus (ocrelizumab
  type: UNKNOWN
  weight: 1.0
- name: European Medicines Agency Committee for Medicinal Products for Human Use (CHMP
  type: UNKNOWN
  weight: 1.0
- name: British Government
  type: organization
  weight: 1.0
- name: Texas_Rangers
  type: organization
  weight: 1.0
computed_at: '2026-09-18T13:49:31Z'
---

# Biosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Document

## TL;DR
The Food and Drug Administration (FDA or Agency) is announcing the publication of a draft strategy document titled "BsUFA III Future Needs in the Development of Interchangeable Products Post-Workshop Strategy Document" (Strategy Document). This draft Strategy Document is intended to summarize the discussion that occurred at the FDA public workshop, "Advancing the Development of Interchangeable Products: Identifying Future Needs," held on September 19, 2025, and to describe FDA's future directions to support interchangeable biosimilar products. FDA is issuing this draft Strategy Document to fulfill a commitment FDA made in the Biosimilar User Fee Act (BsUFA) reauthorization commitment letter for fiscal years 2023 through 2027 (BsUFA III) to publish a post-workshop draft strategy document for public comment.

## Key Points
- (なし)

## Details
(本文なし。リンク先参照)

## Source
元記事: [Biosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Document](https://www.federalregister.gov/documents/2026/09/18/2026-19166/biosimilar-user-fee-act-iii-future-needs-in-the-development-of-interchangeable-products) — published 2026-09-18T00:00:00Z
